Table 2.
Demographic and clinical characteristics of patients with PPP
| Demographic characteristic | US MarketScan | German disease analyzer | ||||
|---|---|---|---|---|---|---|
| All patients with PPP | Patients with PPP & plaque PsO | Patients with PPP without plaque PsO | All patients with PPP | Patients with PPP & plaque PsO | Patients with PPP without plaque PsO | |
| N | 1629 | 392 | 1237 | 3866 | 481 | 3385 |
| Age | ||||||
| Mean (SD) | 54.1 (11.7) | 54.3 (10.9) | 54.1 (12.0) | 56.9 (14.3) | 56.1 (14.7) | 57.0 (14.2) |
| Median (25th, 75th) | 56 (48, 61) | 56 (48, 61) | 56 (48, 61) | 58 (49, 66) | 57 (47, 66) | 58 (50, 66) |
| Min, Max | 18, 91 | 18, 87 | 18, 91 | 18, 95 | 18, 95 | 18, 94 |
| Age group (n [%]) | ||||||
| 18–39 years | 181 (11.1) | 39 (10.0) | 142 (11.5) | 515 (13.3) | 75 (15.6) | 440 (13.0) |
| 40–64 years | 1266 (77.7) | 317 (80.9) | 949 (76.7) | 2224 (57.5) | 269 (55.9) | 1955 (57.8) |
| 65–74 years | 120 (7.4) | 24 (6.1) | 96 (7.8) | 712 (18.4) | 82 (17.0) | 630 (18.6) |
| ≥ 75 years | 62 (3.8) | 12 (3.1) | 50 (4.0) | 415 (10.7) | 55 (11.4) | 360 (10.6) |
| Gender (n [%]) | ||||||
| Female | 1161 (71.3) | 271 (69.1) | 890 (71.9) | 2620 (67.8) | 297 (61.7) | 2323 (68.6) |
| Male | 468 (28.7) | 121 (30.9) | 347 (28.1) | 1246 (32.2) | 184 (38.3) | 1062 (31.4) |
| Treatment–naïve (n [%]) | ||||||
| Yes | 326 (20.0) | 30 (7.7) | 296 (23.9) | 2287 (59.2) | 82 (17.0) | 2205 (65.1) |
| No | 1303 (80.0) | 362 (92.3) | 941 (76.1) | 1579 (40.8) | 399 (83.0) | 1180 (34.9) |
| Medication history (n [%]) | ||||||
| Topical agent | 1037 (63.7) | 306 (78.1) | 731 (59.1) | 1334 (34.5) | 356 (74.0) | 978 (28.9) |
| Oral agent | 777 (47.7) | 219 (55.9) | 558 (45.1) | 481 (12.4) | 121 (25.2) | 360 (10.6) |
| Biologic agent | 284 (17.4) | 126 (32.1) | 158 (12.8) | 81 (2.1) | 35 (7.3) | 46 (1.4) |
| Phototherapy | 81 (5.0) | 50 (12.8) | 31 (2.5) | – | – | – |
| Year of diagnosis (n [%]) | ||||||
| 2016 | 296 (18.2) | 90 (23.0) | 206 (16.7) | 370 (9.6) | 54 (11.2) | 316 (9.3) |
| 2017 | 425 (26.1) | 120 (30.6) | 305 (24.7) | 1016 (26.3) | 131 (27.2) | 885 (26.1) |
| 2018 | 336 (20.6) | 72 (18.4) | 264 (21.3) | 836 (21.6) | 92 (19.1) | 744 (22.0) |
| 2019 | 305 (18.7) | 64 (16.3) | 241 (19.5) | 801 (20.7) | 101 (21.0) | 700 (20.7) |
| 2020 | 248 (15.2) | 43 (11.0) | 205 (16.6) | 682 (17.6) | 87 (18.1) | 595 (17.6) |
| 2021 | 19 (1.2) | 3 (0.8) | 16 (1.3) | 161 (4.2) | 16 (3.3) | 145 (4.3) |
| Baseline comorbidities (n [%]) | ||||||
| Hypertension | 560 (34.4) | 133 (33.9) | 427 (34.5) | 243 (6.3) | 24 (5.0) | 219 (6.5) |
| Hyperlipidemia | 498 (30.6) | 123 (31.4) | 375 (30.3) | 94 (2.4) | 8 (1.7) | 86 (2.5) |
| Pustulotic arthro–osteitisa | 272 (16.7) | 56 (14.3) | 216 (17.5) | 278 (7.2) | 20 (4.2) | 258 (7.6) |
| Diabetes mellitus | 243 (14.9) | 58 (14.8) | 185 (15.0) | 112 (2.9) | 7 (1.5) | 105 (3.1) |
| Thyroid disorders | 204 (12.5) | 46 (11.7) | 158 (12.8) | 71 (1.8) | 8 (1.7) | 63 (1.9) |
|
Cardiovascular disease |
178 (10.9) | 32 (8.2) | 146 (11.8) | 111 (2.9) | 13 (2.7) | 98 (2.9) |
| Anxiety | 177 (10.9) | 43 (11.0) | 134 (10.8) | 38 (1.0) | 3 (0.6) | 35 (1.0) |
| SAPHO | 162 (9.9) | 27 (6.9) | 135 (10.9) | 95 (2.5) | 16 (3.3) | 79 (2.3) |
| Depression | 161 (9.9) | 43 (11.0) | 118 (9.5) | 124 (3.2) | 19 (4.0) | 105 (3.1) |
| Psoriatic arthritis | 143 (8.8) | 53 (13.5) | 90 (7.3) | 98 (2.5) | 34 (7.1) | 64 (1.9) |
| Sinusitis | 99 (6.1) | 23 (5.9) | 76 (6.1) | 47 (1.2) | 5 (1.0) | 42 (1.2) |
| Asthma | 92 (5.7) | 19 (4.9) | 73 (5.9) | 26 (0.7) | 2 (0.4) | 24 (0.7) |
| Rheumatoid arthritis | 83 (5.1) | 17 (4.3) | 66 (5.3) | 40 (1.0) | 6 (1.2) | 34 (1.0) |
| Inflammatory bowel disease | 39 (2.4) | 7 (1.8) | 32 (2.6) | 13 (0.3) | 1 (0.2) | 12 (0.4) |
| Atopic dermatitis | 38 (2.3) | 13 (3.3) | 25 (2.0) | 122 (3.2) | 15 (3.1) | 107 (3.2) |
| Allergies | 27 (1.7) | 11 (2.8) | 16 (1.3) | 57 (1.5) | 7 (1.5) | 50 (1.5) |
| Non–alcoholic fatty liver disease | 25 (1.5) | 8 (2.0) | 17 (1.4) | 18 (0.5) | 2 (0.4) | 16 (0.5) |
| Renal impairment | 15 (0.9) | 4 (1.0) | 11 (0.9) | 5 (0.1) | – | 5 (0.1) |
| Ankylosing spondylitis | 10 (0.6) | – | 10 (0.8) | 13 (0.3) | – | 13 (0.4) |
| Cutaneous lupus erythematosus | 6 (0.4) | – | 6 (0.5) | 13 (0.3) | 3 (0.6) | 10 (0.3) |
| Behcet's disease | 2 (0.1) | – | 2 (0.2) | – | – | – |
| Celiac disease | 2 (0.1) | – | 2 (0.2) | – | – | – |
| Tonsillitis | 2 (0.1) | – | 2 (0.2) | 21 (0.5) | 3 (0.6) | 18 (0.5) |
| Dental infection | 1 (0.1) | 1 (0.3) | – | 1 (0.0) | – | 1 (0.0) |
| Streptococcal infection | 1 (0.1) | – | 1 (0.1) | 3 (0.1) | 1 (0.2) | 2 (0.1) |
| Tuberculosis | 1 (0.1) | 1 (0.3) | – | – | – | – |
PPP palmoplantar pustulosis; PsO psoriasis; SAPHO synovitis, acne, pustulosis, hyperostosis, osteitis
aPustulotic arthro-osteitis identified as having analgesic/NSAIDs use, topical antibiotic use, or a sternum-clavicular procedure ± 30 days of a PPP diagnosis.